Comment from ASCO President Douglas W. Blayney, MD, on the FDA's Rule to Expand Patient Access to Investigational Drugs

FOR IMMEDIATE RELEASE
August 16, 2009
Contact: 

Aaron Tallent
571-483-1371
aaron.tallent@asco.org

ALEXANDRIA, Va. - "ASCO is pleased that the FDA has issued new rules that strike a balance between meeting the immediate needs of seriously ill cancer patients today, while safeguarding the clinical trials system so it can develop new drugs to treat cancer patients in the future.

"The new rules will make it clearer for doctors and patients to access experimental drugs when other treatment options have been exhausted and clinical trials are not available.

"ASCO will be developing tools to ensure that oncologists understand the new rules and can help their patients benefit.”